{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T20:28:33Z","timestamp":1773692913233,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013116","name":"Merz Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013116","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.parkreldis.2012.02.008","type":"journal-article","created":{"date-parts":[[2012,3,9]],"date-time":"2012-03-09T04:03:13Z","timestamp":1331265793000},"page":"441-445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin\u00ae: A new botulinum neurotoxin A"],"prefix":"10.1016","volume":"18","author":[{"given":"Fernando L.","family":"Pagan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2012.02.008_bib1","series-title":"Xeomin prescribing information","author":"Merz Pharmaceuticals LLC","year":"2010"},{"issue":"Suppl. 2","key":"10.1016\/j.parkreldis.2012.02.008_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2009.02879.x","article-title":"Xeomin: an innovative new botulinum toxin type A","volume":"16","author":"Frevert","year":"2009","journal-title":"Eur J Neurol"},{"issue":"13","key":"10.1016\/j.parkreldis.2012.02.008_bib3","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX(R)) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.02.008_bib4","series-title":"International Conference on Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins; 23\u201325 June 2005; Denver, Colorado: Neurotoxicity Research","article-title":"Comparative antigenicity of three preparations of botulinum neurotoxin type A in rabbits. (Poster)","author":"Bluemel","year":"2006"},{"issue":"Suppl. 2","key":"10.1016\/j.parkreldis.2012.02.008_bib5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1468-1331.2009.02878.x","article-title":"Xeomin in the treatment of cervical dystonia","volume":"16","author":"Benecke","year":"2009","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2012.02.008_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.2340\/16501977-0796","article-title":"Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity","volume":"43","author":"Kanovsky","year":"2011","journal-title":"J\u00a0Rehab Med"},{"issue":"5","key":"10.1016\/j.parkreldis.2012.02.008_bib7","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2165\/00003495-200767050-00003","article-title":"Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia","volume":"67","author":"Jost","year":"2007","journal-title":"Drugs"},{"issue":"Suppl. (0)","key":"10.1016\/j.parkreldis.2012.02.008_bib8","first-page":"40","article-title":"High doses of NT 201 (Xeomin\u00ae) do not alter gastro-intestinal motility","volume":"51","author":"Janaitis","year":"2008","journal-title":"Toxicon"},{"issue":"Suppl. 1","key":"10.1016\/j.parkreldis.2012.02.008_bib9","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.toxicon.2008.04.038","article-title":"Xeomin is stable without refrigeration: complexing proteins are not required for stability of botulinum neurotoxin type A preparations.","volume":"51","author":"Grein","year":"2008","journal-title":"Toxicon"},{"issue":"5","key":"10.1016\/j.parkreldis.2012.02.008_bib10","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.toxicon.2009.03.010","article-title":"Xeomin is free from complexing proteins","volume":"54","author":"Frevert","year":"2009","journal-title":"Toxicon"},{"issue":"8","key":"10.1016\/j.parkreldis.2012.02.008_bib11","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/mds.23658","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-A randomized trial","volume":"26","author":"Jankovic","year":"2011","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.parkreldis.2012.02.008_bib12","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.WNF.0000240951.18821.50","article-title":"Neurophysiological double-blind trial of a botulinum neurotoxin type a free of complexing proteins","volume":"30","author":"Wohlfarth","year":"2007","journal-title":"Clin Neuropharmacol"},{"issue":"Suppl. 2","key":"10.1016\/j.parkreldis.2012.02.008_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1468-1331.2009.02877.x","article-title":"Routine use of Xeomin in patients previously treated with Botox: long term results","volume":"16","author":"Dressler","year":"2009","journal-title":"Eur J Neurol"},{"issue":"Suppl. (0)","key":"10.1016\/j.parkreldis.2012.02.008_bib14","first-page":"10","article-title":"Equivalent potency of Xeomin\u00ae and BOTOX\u00ae","volume":"51","author":"Dressler","year":"2008","journal-title":"Toxicon"},{"issue":"2","key":"10.1016\/j.parkreldis.2012.02.008_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2165\/11584780-000000000-00000","article-title":"Content of botulinum neurotoxin in Botox(R)\/Vistabel(R), Dysport(R)\/Azzalure(R), and Xeomin(R)\/Bocouture(R)","volume":"10","author":"Frevert","year":"2010","journal-title":"Drugs R&D"},{"issue":"11","key":"10.1016\/j.parkreldis.2012.02.008_bib16","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1212\/01.WNL.0000163767.99354.C3","article-title":"A\u00a0new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia","volume":"64","author":"Benecke","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2012.02.008_bib17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00702-005-0323-3","article-title":"Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm","volume":"113","author":"Roggenk\u00e4mper","year":"2006","journal-title":"J\u00a0Neural Transm"},{"issue":"Suppl. 4","key":"10.1016\/j.parkreldis.2012.02.008_bib18","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1111\/j.1524-4725.2010.01706.x","article-title":"Noninferiority of incobotulinumtoxin A, free from complexing proteins, compared with another botulinum toxin type A in the treatment of glabellar frown lines","volume":"36","author":"Sattler","year":"2010","journal-title":"Dermatol surg"},{"issue":"7","key":"10.1016\/j.parkreldis.2012.02.008_bib19","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00702-004-0234-8","article-title":"Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers","volume":"112","author":"Jost","year":"2005","journal-title":"J\u00a0Neural Transm"},{"issue":"1\u20132","key":"10.1016\/j.parkreldis.2012.02.008_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxin A (NT 201, XEOMIN(R)), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.parkreldis.2012.02.008_bib21","series-title":"International Congress of Parkinson\u2019s Disease and Movement Disorders; June 7\u201311 2009; Paris, France: Movement Disorders","first-page":"S92","article-title":"Efficacy and safety of NT 201: botulinum neurotoxin type A free from complexing proteins, in treatment-naive cervical dystonia patients. (Abstract Tu-401)","author":"Grafe","year":"2009"},{"key":"10.1016\/j.parkreldis.2012.02.008_bib22","series-title":"Efficacy and safety of NT 201: botulinum neurotoxin type A free from complexing proteins, in treatment-naive cervical dystonia patients. (Abstract Tu-400). In: International Congress of Parkinson\u2019s Disease and Movement Disorders","year":"2009"},{"key":"10.1016\/j.parkreldis.2012.02.008_bib23","doi-asserted-by":"crossref","unstructured":"Grafe S, Hanschmann A. Safety and efficacy of repeated NT 201 (botulinum neurotoxin type A free from complexing proteins) injections of patients with cervical dystonia: a first long-term safety analysis. [P01.270]. Presented at: Annual Meeting of the American Academy of Neurology; 10\u201317 April 2010; Toronto, Ontario, Canada.","DOI":"10.1016\/j.pmrj.2010.07.080"},{"issue":"Suppl. 2","key":"10.1016\/j.parkreldis.2012.02.008_bib24","first-page":"II","article-title":"Safety aspects of high dose Xeomin\u00ae therapy. Presented at: European Neurological Society; 27\u201331 May 2006; Lausanne, Switzerland","volume":"253","author":"Dressler","year":"2006","journal-title":"J\u00a0Neurol"},{"issue":"23","key":"10.1016\/j.parkreldis.2012.02.008_bib25","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/09638280701568296","article-title":"Pharmacology of therapeutic botulinum toxin preparations","volume":"29","author":"Dressler","year":"2007","journal-title":"Disabil Rehab"},{"issue":"Suppl. 2","key":"10.1016\/j.parkreldis.2012.02.008_bib26","first-page":"46","article-title":"In\u00a0vitro stability of botulinum toxin complex at physiological pH and temperature","volume":"365","author":"Friday","year":"2002","journal-title":"Naunyn-Schmiedeberg\u2019s Arch Pharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.parkreldis.2012.02.008_bib27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2006.01439.x","article-title":"Immunological aspects of Botox\u00ae, Dysport\u00ae and Myobloc\u2122\/NeuroBloc\u00ae.","volume":"13","author":"Dressler","year":"2006","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.parkreldis.2012.02.008_bib28","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/NRL.0b013e31816f2cdd","article-title":"Clinical comparisons of botulinum neurotoxin formulations","volume":"14","author":"Brashear","year":"2008","journal-title":"Neurologist"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802012000661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802012000661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:13:19Z","timestamp":1761178399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802012000661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1353802012000661"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2012.02.008","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin\u00ae: A new botulinum neurotoxin A","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2012.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}